
Vertex Pharmaceuticals Incorporated (VRTX) rises on FDA win
Vertex Pharmaceuticals Incorporated (VRTX) rises after the FDA expands CASGEVY for younger patients with sickle cell disease and beta thalassemia. The approval widens the therapy’s addressable market, strengthens Vertex’s rare-disease growth story, and sends the stock to a fresh 52-week high.


